Tolerance Profile of the Proliferation Signal Inhibitors Everolimus and Sirolimus in Heart Transplantation

Transplantation Proceedings

Volumn 40, Issue 9, 2008, Pages 3034-3036

  Moro, J A ^a,b   Almenar, L ^b   Martinez Dolz L ^b   Sanchez Lazaro I ^b   Aguero J ^b   Salvador, A ^b  

^a Research Foundation   (Spain)

^b Cardiology Unit   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; RAPAMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG TOLERANCE; DRUG WITHDRAWAL; EDEMA; FEMALE; HEART TRANSPLANTATION; HUMAN; INFECTION; KAPLAN MEIER METHOD; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STUDENT T TEST;

ADULT; CALCINEURIN; CARDIOMYOPATHY, DILATED; CORONARY DISEASE; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; EDEMA; FEMALE; FOLLOW-UP STUDIES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; MALE; MIDDLE AGED; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 56049097497     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2008.09.049     Document Type: Article

References (8)

1. Lindenfeld J., Miller G.G., and Shakar S.F. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. Circulation 110 (2004) 3858
2. Moro J., Almenar L., and Martínez-Dolz L. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study. Transplant Proc 39 (2007) 2365
3. Eisen H.J., Tuzcu E.M., Dorent R., and RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients. N Engl J Med 349 (2003) 847
4. Vitko S., Margreiter R., and Weimar W. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 5 (2005) 2521
5. Lorber M.I., Mulgaonkar S., and Butt K.M. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 80 (2005) 244
6. Pascual J., Marcen R., and Ortuno J. Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 79 (2005) S80
7. Mahe E., Morelon E., and Lechaton S. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 79 (2005) 476
8. Vitko S., Margreiter R., and Weimar. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 78 (2004) 1532